





### **Methylation profiling report**

**General information** 

Sentrix ID: 202013790192\_R01C01

Array type: EPIC

Material type: KRYO DNA

Gender: male

#### Brain tumor methylation classifier results (v11b4)

Methylation classes (MCs with score >= 0.3)	Calibrated score	Interpretation	
methylation class family Glioma, IDH mutant	0.99	match	<b>~</b>
MC family members with score >= 0.1			
methylation class IDH glioma, subclass 1p/19q codeleted oligodendroglioma	0.99	match	•
Legend: ✓ Match (score >= 0.9) X No match (score < 0.9): possibly still relevant for low tumor content and legend: ✓ match (score >= 0.9)	ow DNA • Match to M (score >= 0	,	ber

#### Class descriptions

Methylation class family Glioma, IDH mutant: The methylation class family "Glioma, IDH mutant" comprises the methylation classes astrocytoma, IDH mutant, astrocytoma, IDH mutant, subtype high grade and oligodendroglioma, IDH mutant and 1p/19q codeleted.

Methylation class IDH glioma, subclass 1p/19q codeleted oligodendroglioma: The methylation class "IDH glioma, subclass 1p/19q codeleted oligodendroglioma" exclusively comprises tumors with the diagnosis anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted and oligodendroglioma, IDH-mutant and 1p/19q-codeleted. All tumors have a supratentorial location and frequently involve the frontal lobe; median age is 44 years (range 18 to 78). Molecularly, this class shares an IDH mutation-associated glioma CIMP, complete 1p/19q codeletion and TERT promoter mutation. A missing complete 1p/19q codeletion is not compatible with this diagnosis. Cases with elevated scores for this class but no complete 1p/19q codeletion likely represent "IDH glioma, subclass astrocytoma" or "IDH glioma, subclass high grade astrocytoma". Copy number analysis shows complete chromosome 1p and 19q loss in all cases. Around 30% of cases additionally show loss of chromosome 4.

#### Copy number variation profile

# 

Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment. (see Hovestadt & Zapatka, http://www.bioconductor.org/packages/devel/bioc/html/conumee.html)

## MGMT promotor methylation (MGMT-STP27)

MGMT promotor status prediction



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

#### **Disclaimer**

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

#### **Run information**

Report: idat\_reportBrain\_v11b4 Version 2.0 Task version:

Tá	ask	Version
id	at_qc	2.0
id	at_predictBrain	2.1
id	at_rs_gender	2.0
id	at_predictMGMT	2.0
id	at_cnvp	3.0